The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
ELISA: Use at a concentration of 1 µg/ml.
Not yet tested in other applications.
Optimal dilutions/concentrations should be determined by the end user.
Influenza A virus is a major public health threat, killing more than 30,000 people per year in the USA. In early 2009, a novel Swine H1N1 Neuraminidase virus was identified in specimens obtained from patients in Mexico and the United States. Influenza A virus has one of sixteen possible Hemagglutinin (HA) surface proteins and one of nine possible Neuraminidase (NA) surface proteins. The genetic make-up of this swine flu virus is unlike any other: it is an H1N1 strain that combines a triple assortment first identified in 1998 including human, swine, and avian influenza with two new pig H3N2 virus genes from Eurasia, themselves of recent Human origin. The distinct antigenic properties of the new Swine H1N1 Neuraminidase virus compared with seasonal influenza A (H1N1) virus suggest that Human immunity against the new virus is limited.
S-OIV A NA antibody
S-OIV A Neuraminidase antibody
Swine flu N1 antibody
Swine-Origin Influenza A (H1N1) Neuraminidase antibody